273 related articles for article (PubMed ID: 16652371)
1. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
[TBL] [Abstract][Full Text] [Related]
2. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.
Lu X; Nannenga B; Donehower LA
Genes Dev; 2005 May; 19(10):1162-74. PubMed ID: 15870257
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
4. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D.
Lu X; Nguyen TA; Donehower LA
Cell Cycle; 2005 Aug; 4(8):1060-4. PubMed ID: 15970689
[TBL] [Abstract][Full Text] [Related]
5. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair.
Lu X; Bocangel D; Nannenga B; Yamaguchi H; Appella E; Donehower LA
Mol Cell; 2004 Aug; 15(4):621-34. PubMed ID: 15327777
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase.
Fujimoto H; Onishi N; Kato N; Takekawa M; Xu XZ; Kosugi A; Kondo T; Imamura M; Oishi I; Yoda A; Minami Y
Cell Death Differ; 2006 Jul; 13(7):1170-80. PubMed ID: 16311512
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
8. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
[TBL] [Abstract][Full Text] [Related]
10. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
Fuku T; Semba S; Yutori H; Yokozaki H
Pathol Int; 2007 Sep; 57(9):566-71. PubMed ID: 17685927
[TBL] [Abstract][Full Text] [Related]
11. PP2Cdelta (Ppm1d, WIP1), an endogenous inhibitor of p38 MAPK, is regulated along with Trp53 and Cdkn2a following p38 MAPK inhibition during mouse preimplantation development.
Hickson JA; Fong B; Watson PH; Watson AJ
Mol Reprod Dev; 2007 Jul; 74(7):821-34. PubMed ID: 17219434
[TBL] [Abstract][Full Text] [Related]
12. Wild-type p53-induced phosphatase 1 (Wip1) forestalls cellular premature senescence at physiological oxygen levels by regulating DNA damage response signaling during DNA replication.
Sakai H; Fujigaki H; Mazur SJ; Appella E
Cell Cycle; 2014; 13(6):1015-29. PubMed ID: 24552809
[TBL] [Abstract][Full Text] [Related]
13. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase.
Shreeram S; Hee WK; Demidov ON; Kek C; Yamaguchi H; Fornace AJ; Anderson CW; Appella E; Bulavin DV
J Exp Med; 2006 Dec; 203(13):2793-9. PubMed ID: 17158963
[TBL] [Abstract][Full Text] [Related]
14. DNA damage signaling induced by the G-quadruplex ligand 12459 is modulated by PPM1D/WIP1 phosphatase.
Douarre C; Mergui X; Sidibe A; Gomez D; Alberti P; Mailliet P; Trentesaux C; Riou JF
Nucleic Acids Res; 2013 Apr; 41(6):3588-99. PubMed ID: 23396447
[TBL] [Abstract][Full Text] [Related]
15. Absence of Wip1 partially rescues Atm deficiency phenotypes in mice.
Darlington Y; Nguyen TA; Moon SH; Herron A; Rao P; Zhu C; Lu X; Donehower LA
Oncogene; 2012 Mar; 31(9):1155-65. PubMed ID: 21765465
[TBL] [Abstract][Full Text] [Related]
16. A protein phosphatase feedback mechanism regulates the basal phosphorylation of Chk2 kinase in the absence of DNA damage.
Carlessi L; Buscemi G; Fontanella E; Delia D
Biochim Biophys Acta; 2010 Oct; 1803(10):1213-23. PubMed ID: 20599567
[TBL] [Abstract][Full Text] [Related]
17. Wip1 phosphatase modulates ATM-dependent signaling pathways.
Shreeram S; Demidov ON; Hee WK; Yamaguchi H; Onishi N; Kek C; Timofeev ON; Dudgeon C; Fornace AJ; Anderson CW; Minami Y; Appella E; Bulavin DV
Mol Cell; 2006 Sep; 23(5):757-64. PubMed ID: 16949371
[TBL] [Abstract][Full Text] [Related]
18. The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase.
Oliva-Trastoy M; Berthonaud V; Chevalier A; Ducrot C; Marsolier-Kergoat MC; Mann C; Leteurtre F
Oncogene; 2007 Mar; 26(10):1449-58. PubMed ID: 16936775
[TBL] [Abstract][Full Text] [Related]
19. p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors.
Park JY; Song JY; Kim HM; Han HS; Seol HS; Jang SJ; Choi J
Int J Biochem Cell Biol; 2012 Jun; 44(6):896-904. PubMed ID: 22405851
[TBL] [Abstract][Full Text] [Related]
20. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.
Lu X; Nguyen TA; Moon SH; Darlington Y; Sommer M; Donehower LA
Cancer Metastasis Rev; 2008 Jun; 27(2):123-35. PubMed ID: 18265945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
